Biopharmaceutical group UCB reported a 17% increase in revenue last year, reaching €6.15 billion. Net sales also rose by 15%, amounting to €5.61 billion.
UCB's underlying profitability (adjusted EBITDA - earnings before interest, taxes, depreciation, and amortisation) grew by 9% to €1.48 billion, representing 24% of total revenue.
For 2025, the company forecasts revenue growth to between €6.5 billion and €6.7 billion. Adjusted EBITDA is expected to reach 30% of revenue.
"The year 2024 was a success, showcasing UCB's innovation and strong execution capabilities, which led to robust financial performance and achieving the €6 billion target ahead of schedule," CFO Sandrine Dufour stated.
"Once again, we met our financial objectives. We will continue our growth trajectory by supporting product launches, investing in groundbreaking innovations, and strategically positioning our portfolio."
This year, UCB is also exploring nine innovative and potential medicines. The company claims to reach over 3.1 million patients worldwide who suffer from severe autoimmune and neurological conditions.
